A5081426704- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- Nanoplatforms for cancer theranostics
- Cancer Mechanisms and Therapy
- Gene Regulatory Network Analysis
- Veterinary Oncology Research
- Cervical Cancer and HPV Research
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Immune Response and Inflammation
- Chemokine receptors and signaling
- Neuroinflammation and Neurodegeneration Mechanisms
- Microbial infections and disease research
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
NGM Biopharmaceuticals (United States)
2025
Cornell University
2013-2023
Swim Across America
2013-2023
Memorial Sloan Kettering Cancer Center
2013-2022
Parker Institute for Cancer Immunotherapy
2022
University of Pennsylvania
2013
Kettering University
2013
Ligation of GITR (glucocorticoid-induced tumor necrosis factor (TNF) receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early phase clinical trials for the treatment advanced malignancies. Although ability modulation to induce regression is well-documented in preclinical studies, underlying mechanisms action, particularly its effects on CD4(+)foxp3(+) regulatory T cells (Treg), have not been fully elucidated. We previously demonstrated that ligation vivo DTA-1...
Variability within isogenic T cell populations yields heterogeneous 'local' signaling responses to shared antigenic stimuli, but responding clones may communicate 'global' antigen load through paracrine messengers, such as cytokines. Such coordination of individual multicellular is critical for accurate collective reactions environmental cues. However, cytokine production saturate a function input, or be dominated by the precursor frequency antigen-specific cells. Surprisingly, we found that...
Transcription factors ThPOK and Runx3 regulate the differentiation of “helper” CD4+ “cytotoxic” CD8+ T cell lineages respectively, inducing single positive (SP) cells that enter periphery with expression either CD4 or CD8 co-receptor. Despite expectation these fates are mutually exclusive mature CD4+CD8+ double (DP) present in healthy individuals augmented context disease, yet their molecular features pathophysiologic role disputed. Here, we show DP murine human tumors as a heterogenous...
Abstract Induction of potent immune responses to self-antigens remains a major challenge in tumor immunology. We have shown that vaccine based on alphavirus replicon particles (VRP) activates strong cellular and humoral immunity tyrosinase-related protein-2 (TRP2) melanoma antigen, providing prophylactic therapeutic effects stringent mouse models. Here, we report the immunogenicity efficacy this is increased combination with either antagonist anti-CTL antigen-4 (CTLA-4) or agonist...
Abstract Tertiary lymphoid structures (TLS) are lymph node-like that form in response to inflammation and facilitate immune activation within the local microenvironment. TLS prevalence solid tumors has been associated with more favorable prognosis checkpoint inhibitors, findings have led hypothesis inducing formation significant therapeutic potential. Lymphotoxin beta receptor (LTBR) is a member of tumor necrosis factor (TNF) superfamily activated upon binding lymphotoxin αββ (LTαββ) or...
Abstract Current approaches to cancer immunotherapy aim enhance the natural T cell response against tumors; however, these treatments may fall short due negative selection of tumor antigen specific cells. To determine how frequency CD4+ cells shape an anti-tumor we have developed a model in which precursor number can be manipulated mice bearing implantable melanoma through adoptive transfer We previously shown that lower frequencies CD8+ for gp100 generate most productive intraclonal...
<p>PDF file - 48K</p>
<p>PDF file - 143K, Foxp3 loss in Tregs is tumor and DTA-1 dose dependent</p>
<p>PDF file - 84K, Percentage of CD4+Foxp3+ Tregs in IgG vs DTA-1 treated tumors</p>
<div>Abstract<p>Ligation of GITR (glucocorticoid-induced TNF receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early-phase clinical trials for the treatment advanced malignancies. Although ability modulation to induce tumor regression is well documented in preclinical studies, underlying mechanisms action, particularly its effects on CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Treg), have not been fully elucidated....
<div>Abstract<p>Induction of potent immune responses to self-antigens remains a major challenge in tumor immunology. We have shown that vaccine based on alphavirus replicon particles (VRP) activates strong cellular and humoral immunity tyrosinase-related protein-2 (TRP2) melanoma antigen, providing prophylactic therapeutic effects stringent mouse models. Here, we report the immunogenicity efficacy this is increased combination with either antagonist anti-CTL antigen-4 (CTLA-4) or...
<div>Abstract<p>Induction of potent immune responses to self-antigens remains a major challenge in tumor immunology. We have shown that vaccine based on alphavirus replicon particles (VRP) activates strong cellular and humoral immunity tyrosinase-related protein-2 (TRP2) melanoma antigen, providing prophylactic therapeutic effects stringent mouse models. Here, we report the immunogenicity efficacy this is increased combination with either antagonist anti-CTL antigen-4 (CTLA-4) or...
<p>PDF file - 428K, Supplementary Figure S1. Depigmentation after combination therapy. S2. Tumor immune infiltrate immunomodulation. S3. PD-1 expression on T cell subsets. S4. Effect of anti-CTLA4 TILs.</p>
<p>PDF file - 428K, Supplementary Figure S1. Depigmentation after combination therapy. S2. Tumor immune infiltrate immunomodulation. S3. PD-1 expression on T cell subsets. S4. Effect of anti-CTLA4 TILs.</p>
<p>PDF file - 48K</p>
<p>PDF file - 84K, Percentage of CD4+Foxp3+ Tregs in IgG vs DTA-1 treated tumors</p>
<p>PDF file - 143K, Foxp3 loss in Tregs is tumor and DTA-1 dose dependent</p>
<div>Abstract<p>Ligation of GITR (glucocorticoid-induced TNF receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early-phase clinical trials for the treatment advanced malignancies. Although ability modulation to induce tumor regression is well documented in preclinical studies, underlying mechanisms action, particularly its effects on CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Treg), have not been fully elucidated....